Olaparib for BRCA-Mutated Relapsed Ovarian Cancer

In patients with platinum-sensitive BRCA-mutated relapsed ovarian cancer, olaparib maintenance therapy significantly increased median overall survival compared with placebo, according to results of the final analysis of the phase 3 SOLO2/ENGOT Ov-21 trial to be presented this coming weekend in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. The trial enrolled 295 patients with BRCA-mutated relapsed ovarian cancer who were previously treated with at least two lin...
Continue reading

Breast Cancer: BRCA1/2 Mutations Enhance Chemotherapy’s Efficacy

Carriers of germline variants in the BRCA1 and BRCA2 genes are more likely to experience a pathologic complete response to two different chemotherapy regimens, according to a retrospective study now published in JAMA Oncology. This study was a secondary analysis of data from the GeparOcto multicenter prospective clinical trial, in which 945 women with different subtypes of high-risk, early-stage breast cancer were randomized to receive either sequential intense dose-dense epirubicin/paclitaxel/c...
Continue reading

Olaparib Maintenance for Metastatic Pancreatic Cancer

The phase 3 POLO trial (NCT02184195) reports that maintenance olaparib increases progression-free survival in metastatic pancreatic cancer with germline BRCA mutations. "Metastatic pancreatic cancer is particularly refractory to treatment," Talia Golan, MD, Head of the Sheba Pancreatic Cancer Center at the Oncology Institute of Tel Aviv University's Sheba Medical Center, and colleagues remark in their publication in The New England Journal of Medicine. "Current standard-of-care first-line t...
Continue reading

Cell Repair Uses Chromosome Scanner to Protect Against Cancer

By identifying a type of scanner protein that is used to look for any damaged chromosomes, researchers at the University of Copenhagen have made a new discovery that illuminates the DNA repair process of homologous recombination (HR), which is important to cancer prevention. The cellular repair process, which is crucial for ridding cells of damaged DNA and preventing cancer, involves two repair systems: error-free homologous recombination (HR) and mutagenic non-homologous end-joining. Homologous...
Continue reading

New Targets Identified in BRCA-Mutated Cancers

Researchers at Brigham and Women's Hospital have identified two new genes that can impact BRCA2-deficient cancer through "synthetic lethality," which occurs when a combination of deficiencies in two or more genes leads to cell death that would not occur with one deficiency alone. Inactivation of BRCA1 or BRCA2, both important tumor suppressor genes named for their roles in breast cancer, increases a woman's risk of breast cancer by up to 80% and increases her risk of ovarian cancer by around 50%...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.